Artemisinin-based combination therapies (ACTs) has been adopted as first-line treatments for uncomplicated Plasmodium falciparum malaria as an integral part of the recent success in global malaria control. Between 2010 and 2017, an estimated 2.74 billion treatment courses of ACTs was delivered. However, the efficacy of ACTs is endangered by the emergence of resistance to artemisinin and partner drug which becomes a major threat to malaria elimination. We are delighted to present a cross-journal series to highlight the studies on efficiency of ACTs and implications of antimalarial drug resistance.
Declining responsiveness of childhood Plasmodium falciparum infections to artemisinin-based combination treatments ten years following deployment as first-line antimalarials in Nigeria
The development and spread of artemisinin-resistant Plasmodium falciparum malaria in Greater Mekong Subregion has created impetus for continuing global monitoring of efficacy of artemisinin-based combination ther...
Citation: Infectious Diseases of Poverty 2019 8:69